In the present invention, as a result of detailed research into the expression, over-amplification, mutation and translocation, and the like of FGFR coding genes in a variety of cancer cells, a novel fusion polypeptide obtained by fusion of FGFR3 polypeptide with another polypeptide was identified and isolated in multiple urinary bladder cancer-derived cells and lung cancer cells. By using this fusion polypeptide as a biomarker in cancer therapy with an FGFR inhibitor, it is possible to preemptively prevent the manifestation of side effects in therapy with an FGFR inhibitor and control the therapeutic mode such that the best possible therapeutic results are obtained, and individualized medical treatment is possible.本發明針對各種癌細胞中之FGFR編碼基因之表現、過度擴增、變異及易位等進行詳細研究,對於複數個來自膀胱癌之細胞及肺癌細胞,鑑定並單離出FGFR3多胜肽與其他多胜肽融合而得的新穎融合多胜肽。藉由將本發明之融合多胜肽作為經FGFR抑制劑所為之癌治療中的生物標記而利用,能預防因FGFR抑制劑所為之治療的副作用的表現,且能控制為達到最佳治療效果的治療態樣,可實施個人化醫療。
